Image via Simply Wall St
Last updated
BioMarin Pharmaceutical: Product Launch
FDA accepted supplemental New Drug Application to convert VOXZOGO's accelerated approval to full approval in children with achondroplasia, with PDUFA target action date of February 28, 2027
Source: Simply Wall St
The leadership read
BioMarin Pharmaceutical's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether BioMarin Pharmaceutical backs it with senior go-to-market hires across Americas — that separates a platform move from a one-off.
Market context: This lands while the Talent Market Index reads 100.4 (Neutral) — down 1.1 versus the prior month — and Americas signal share is easing (-1.8pts).
BioMarin Pharmaceutical: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 25 tracked companies.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Bristol Myers Squibb →FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.
Product Launch · Americas
Amgen →Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Product Launch · Americas
Celltrion →Celltrion's Truxima (rituximab biosimilar) received FDA interchangeability status—the first rituximab biosimilar to achieve this designation in the United States. This enables automatic substitution without new prescriptions and grants exclusivity protection.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Where this lands in our work
- Enterprise Innovation & Transformation →
A launch is the output of a product and engineering leadership layer built before it.
- Executive Search — Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record